Intranasal delivery of venlafaxine loaded nanostructured lipid carrier: Risk assessment and QbD based optimization
Authors:
- Brijesh ShahBSBrijesh Shah
- Dignesh KhuntDignesh Khunt
- Himanshu BhattHBHimanshu Bhatt
- Manju MisraMMManju Misra
- Harish PadhHPHarish Padh
- 1 June 2016
- journal article
- Published by Elsevier in Journal of Drug Delivery Science and Technology
- Vol. 33, 37-50
Abstract
No abstract availableFunding Information
- Lady Tata Memorial Trust (Bombay, India), Department of Science and Technology (IFA-LSBM-13)
- Department of Biotechnology (BT/PR6541/GBD/27/438/2012)
- Industries Commissionerate
This publication has 45 references indexed in Scilit:
- The Nasal Approach to Delivering Treatment for Brain Diseases: An Anatomic, Physiologic, and Delivery Technology OverviewTherapeutic Delivery, 2014
- Development and evaluation of brain targeted intranasal alginate nanoparticles for treatment of depressionJournal of Psychiatric Research, 2014
- Intranasal infusion of nanostructured lipid carriers (NLC) containing CNS acting drug and estimation in brain and bloodDrug Delivery, 2013
- Ex vivo permeation characteristics of venlafaxine through sheep nasal mucosaEuropean Journal of Pharmaceutical Sciences, 2013
- Depression: The Disorder and the BurdenIndian Journal of Psychological Medicine, 2010
- Comprehensive Analysis of Remission (COMPARE) with Venlafaxine versus SSRIsBiological Psychiatry, 2008
- Nanoparticulate Systems for Nasal Delivery of Drugs: A Real Improvement over Simple Systems?Journal of Pharmaceutical Sciences, 2007
- VENLAFAXINE INGESTION IS ASSOCIATED WITH RHABDOMYOLYSIS IN ADULTS: A CASE SERIESThe Journal of Toxicological Sciences, 2007
- SNRIs: The Pharmacology, Clinical Efficacy, and Tolerability in Comparison with Other Classes of AntidepressantsCNS Spectrums, 2005
- Venlafaxine: A 2003 updateClinical Therapeutics, 2003